Login to Your Account

Sillajen Will Acquire Jennerex in $150M Deal

By Catherine Shaffer
Staff Writer

Wednesday, November 27, 2013
An acquisition of Jennerex Inc. by Sillajen Inc. may be needed redemption for Jennerex’s recently troubled cancer immunotherapy, Pexa-Vec. The product failed to reach its primary endpoint of overall survival in a Phase IIb trial in September, resulting in a stock plummet for Jennerex’s European partner, Transgene SA.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription